Hong Kong stock surge | Jinfan Pharmaceuticals-B (02595.HK) rose more than 7% in early trading, planning to raise approximately HK$470 million in net proceeds through a rights issue to advance core products such as RAS inhibitors.

According to the Wisdom Finance and Economics APP, Jingfang Medicine-B (02595.HK) surged more than 7% in early trading. As of the time of publication, it was up by 1.51%, at 39 Hong Kong dollars, with a trading volume of 68.3504 million Hong Kong dollars.